Back to Journals Vascular Health and Risk Management Volume 12 SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives Authors Gurgle H, White K, McAdam-Marx C Received 14 November 2015 Accepted for publication 11 March 2016 Published 4 June 2016 Volume 2016:12 Pages 239249 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 5 Editor who approved publication: Dr Daniel Duprez Holly E Gurgle, Karen White, Carrie McAdam-Marx Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA Abstract: Controversy exists regarding the selection of second-line therapy for patients with type 2 diabetes mellitus (T2DM) who are unable to achieve glycemic control with metformin therapy alone
At Cymbiotika, we are dedicated to providing you with trusted, transparent, and effective supplements to empower your health journey
If you do choose to drink, keep it moderate and always have some food with your alcohol to help prevent your blood sugar from dropping too low
Risks include gastrointestinal side effects (nausea, vomiting, diarrhea) that may worsen disordered eating, potential for pancreatitis and gallbladder disease, and unknown psychological impacts in eating disorder populations
